Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:37:57 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



Q:PLSE - PULSE BIOSCIENCES INC - http://investors.pulsebiosciences.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PLSE - Q0.47.52·8.670.17.82-0.23-2.9169.41,2781,0458.09  8.23  7.7313.62  3.7816:01:50May 0215 min RT 2¢

Recent Trades - Last 10 of 1045
Time ETExPriceChangeVolume
16:01:50Q7.82-0.23578
16:00:06Q7.79-0.262
16:00:00Q7.82-0.23355
16:00:00Q7.82-0.2318
16:00:00Q7.82-0.236
16:00:00Q7.82-0.23628
16:00:00Q7.82-0.2318
16:00:00Q7.82-0.232
16:00:00Q7.82-0.23501
16:00:00Q7.82-0.23129

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 08:00U:PLSENews ReleasePulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
2024-04-24 16:05U:PLSENews ReleasePulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
2024-03-28 16:12U:PLSENews ReleasePulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
2024-03-28 16:10U:PLSENews ReleasePulse Biosciences Announces Plans to Initiate a Rights Offering
2024-03-14 16:05U:PLSENews ReleasePulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
2024-03-08 13:17U:PLSENews ReleasePulse Biosciences Announces FDA 510(k) Clearance for its CellFX(TM) nsPFA(TM) Percutaneous Electrode System
2024-02-14 08:00U:PLSENews ReleasePulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX ‚ ® nsPFA ¢ „ ¢ 360 ‚ ° Cardiac Catheter First-in-Human Feasibility Study
2024-01-31 08:00U:PLSENews ReleasePulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
2024-01-02 08:00U:PLSENews ReleasePulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX ‚ ® nsPFA ¢ „ ¢ Cardiac Clamp
2023-12-20 08:00U:PLSENews ReleasePulse Biosciences Announces First-in-Human Procedures with its Novel CellFX ¢ „ ¢ Nanosecond Pulsed Field Ablation (nsPFA ¢ „ ¢) Cardiac Catheter
2023-11-21 08:00U:PLSENews ReleasePulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
2023-11-15 16:05U:PLSENews ReleasePulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-13 08:00U:PLSENews ReleasePulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
2023-11-10 16:56U:PLSENews ReleaseUPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
2023-10-30 16:05U:PLSENews ReleasePulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
2023-10-24 08:00U:PLSENews ReleasePulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
2023-10-02 08:00U:PLSENews ReleasePulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
2023-09-29 08:00U:PLSENews ReleasePulse Biosciences ¢ € ™ Nanosecond Pulsed Field Ablation (nsPFA ¢ „ ¢) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
2023-09-27 08:00U:PLSENews ReleasePulse Biosciences ¢ € ™ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
2023-09-07 16:05U:PLSENews ReleasePulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase